eBook: Optimizing Cell Therapy Products with IsoPlexis Proteomics and Excellos: Starting Material and Manufacturing Characterization

Cell therapies such as chimeric antigen receptor (CAR)-T and tumor infiltrating lymphocyte (TIL) therapies are a paradigm shift in medicine, greatly improving outcomes in a number of different types of cancers. Expanding on the indications, however, has proven challenging, as clinical trials have shown low overall response rates and unfavorable frequencies of relapse and recurrence. To improve clinical response, researchers are looking to optimize characterization of starting material and manufacturing processes, with the potential that more consistent cell therapy products will increase clinical benefits.

In this eBook, we explore the factors that contribute to clinical variability and how to address them through improved characterization and manufacturing processes. Topics covered include:

  • Product active pharmaceutical ingredient (API) challenges with cell therapies
  • Manufacturing considerations to optimize cell products
  • Strategies to characterize and monitor cell function
  • How single-cell functional analysis can predict clinical outcomes

Read the full eBook here.

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.